164221-12-9

Usage

Uses

Used in Industrial Applications:
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol is used as a raw material in the production of various industrial products, such as surfactants, lubricants, and plasticizers. Its unique properties make it suitable for various chemical and industrial processes.
Used in Pharmaceutical Industry:
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol has potential applications in the pharmaceutical industry, where it can be utilized for the development of new drugs or as an intermediate in the synthesis of pharmaceutical compounds.
Used in Cosmetic Industry:
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol can also be used in the cosmetic industry, where it may serve as an ingredient in the formulation of skincare products, hair care products, or other cosmetic formulations due to its unique properties.

Upstream product

• 10417-94-4 all cis-5,8,11,14,17-eicosapentaenoic acid 
• 86227-47-6 eicosapentaenoic acid ethyl ester 
• 2566-90-7 all-cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester 
• 2734-47-6 (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-icosapentaenoic acid methyl ester 

Downstream Products

• 1192949-29-3 (all-Z)-5,8,11,14,17-eicosapentaen-1-yl di-methyl-phosphonate 
• 119818-40-5 (7Z,10Z,13Z,16Z,19Z)-ethyl docosa-7,10,13,16,19-pentaenoate 
• 875288-80-5 methyl (2E,7Z,10Z,13Z,16Z,19Z)-docosa-2,7,10,13,16,19-hexaenoate 
• 1253909-49-7 (4S,5R)-3-((R)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoyl)-4-methyl-5-phenyloxazolidin-2-one 
• 1253909-48-6 (4S,5R)-3-((S)-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoyl)-4-methyl-5-phenyloxazolidin-2-one 
• 1316749-16-2 2-((2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoyl)oxy)benzoic acid 
• 1316749-15-1 tert-butyl 2-((2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoyl)oxy)benzoate 
• 1316749-50-4 2-hydroxy-5-(3-(2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethyl)ureido)benzoic acid 
• 1316749-49-1 methyl 2-hydroxy-5-(3-(2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethyl)ureido)benzoate 
• 1316749-43-5 2-hydroxy-5-(((2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethoxy)carbonyl)amino)benzoic acid 
• 1316749-41-3 methyl 2-hydroxy-5-(((2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)ethoxy)carbonyl)amino)benzoate 
• 1316749-40-2 2-hydroxy-5-((2S)-2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)-4-methylpentanamido)benzoic acid 
• 1316749-37-7 methyl 2-hydroxy-5-((2S)-2-(2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanamido)-4-methylpentanamido)benzoate 
• 1316749-23-1 2-hydroxy-N-(2-(2-((5Z,8Z_,11Z_,14Z,17Z)-icosa-5_,8_,11,14,17-pentaen-1-yloxy)butanamido)ethyl)benzamide 

Relevant academic research and scientific papers

A New Lipobetaine from the Red Alga Neodilsea yendoana

A new isosanoid lipobetaine has been isolated from a red alga and its structure has been determined to be (2S)-2--(8Z,11Z,14Z)-8,11,14-icosatrienoylamino>-5-trimethylammoniopentanoate, mainly on the basis of NMR spectral and chemical means.

Molecule, synthesis method and application of polyunsaturated compound

The invention provides a molecule, a synthesis method and application of a polyunsaturated compound. The toxicity of the product to cells is not obvious. Compared with metformin, the compound disclosed by the invention has the advantage that the capability of promoting cell glycometabolism is enhanced. The product provided by the invention has no obvious influence on cell growth under the concentration of 200 uM. Compared with metformin, the concentration of the product for promoting cell glycometabolism is remarkably reduced, and the effective concentration is about 20 times lower than that of metformin. The series of compounds disclosed by the invention have a stronger effect of promoting sugar consumption than metformin, and the action concentration is remarkably reduced.

NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators

The present invention relates to the NSAID derivatives of omega-3 fatty acids as gamma secretase modulators and their use in treating Alzheimer's disease, hypertriglyceridemia, and cardiovascular disease by reducing triglycerides, and for use as anti-inflammatory agents.

METHOD FOR CHEMICAL CONVERSION OF UNSATURATED FATTY ACID BY CARBON CHAIN EXTENSION REACTION

The present invention relates to a method for the chemical conversion of an unsaturated fatty acid, particularly a carbon chain extension reaction. According to the present invention, a method for extending the length of a carbon chain in an unsaturated fatty acid by two carbon atoms is provided, said method comprising a step of heating a malonic acid ester derivative of an unsaturated fatty acid to reflux in a lower fatty acid solution in the presence of an antioxidative agent. It is preferred that the unsaturated fatty acid is an unsaturated fatty acid having 16 to 24 carbon atoms. It is preferred that the unsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, stearidonic acid, icosatetraenoic acid, icosapentaenoic acid, tetracosahexaenoic acid and docosahexaenoic acid. According to the method of the present invention, a carbon chain extension reaction can be completed within a shorter time.

COMPOUND, COMPOSITION AND USES THEREOF

The compositions and compounds of formula I, formula II, formula III which includes a salt of polyunsaturated fatty acids in a molecular conjugate with amino acid isoleucine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection administration. Such compositions may be used to treatment of hyperglycemia, metabolic syndrome, diabetes, pre-diabetes, lowering triglycerides or its associated complications.

Omefibrates for Treating Dyslipidemia and Cardiovascular Disease

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs).

METHODS OF PREPARING FATTY ACID DERIVATIVES

Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.

Concise syntheses of three ω-3 polyunsaturated fatty acids

The synthesis of the three ω-3 polyunsaturated fatty acids, eicosatetraenoic acid (3), docosapentaenoic acid (4), and stearidonic acid (5) has been achieved using eicosapentaenoic acid or docosahexaenoic acid as the starting materials.

PROCESS FOR PREPARING AND PURIFYING FATTY ACIDS

There is provided a process for purifying a fatty acid, which process comprises reacting a fatty acid with a lithium salt in a first solution and under conditions to allow formation of a precipitate of a lithium salt of the fatty acid; isolating the precipitate; dissolving the precipitate in a second solution followed by separation of the organic and aqueous layers so formed; and evaporating the organic layer to isolate the purified fatty acid. There is also provided a process for increasing the length of a fatty acid, and the use of a lithium salt to purify a fatty acid.

SYNTHESIS AND USE OF OMEGA-3 AND OMEGA-6 VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS (VLC-PUFA)

The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC- PUFAs, C28-C42:4,5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.